DEEPNOID Inc (315640) Fair Value & Analysis
Healthcare · KR · Market cap 37.9B KRW
Fair value as of: Jul 22, 2026
From 1 valuation models · updated 19 days ago
Fair value updated Jul 22, 2026, revised from 642.52 KRW to 533.52 KRW (−17.0%) since Jul 9, 2026. Share price +17.7% over the past month.
Below-average quality, and screening another 69% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (666.90 KRW). The favourable scenario is already priced in.
- Weak quality (17/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (352.12 KRW to 666.90 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 1,158 KRW – 14,492 KRW · fair‑value band 352.12 KRW – 666.90 KRW · the 1,729 KRW price screens above the 533.52 KRW fair value. Dashed = 300-day average. As of Jul 22, 2026.
Analysis
DEEPNOID Inc (315640) currently trades at 1,729 KRW, while our model-based Fair Value estimate is 533.52 KRW, implying the stock looks roughly 69.1% overvalued today. The Quality Score stands at 17/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 6.9B KRW. Revenue declined 62.8% year over year. It earns a return on equity of -54.7%. Net debt stands at 2.6B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 352.12 KRW (bear case) to 666.90 KRW (bull case); at 1,729 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 74% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside, at -69%, 315640 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 315640 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 22 · Market factors (momentum, volatility) 16
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
DEEPNOID Inc. provides artificial intelligence solutions for medical and industrial sectors. The company offers various solutions, such as DEEP:NEURO, detects suspected cerebral aneurysm areas in brain through brain MRA images; M4CXR, a CXR reporting solution powered by generative AI; DEEP:CHEST, an AI-based medical image reading assistance solution to …
Full company description
DEEPNOID Inc. provides artificial intelligence solutions for medical and industrial sectors. The company offers various solutions, such as DEEP:NEURO, detects suspected cerebral aneurysm areas in brain through brain MRA images; M4CXR, a CXR reporting solution powered by generative AI; DEEP:CHEST, an AI-based medical image reading assistance solution to detect suspected areas of various diseases in medical images; and DEEP:LUNG, an AI solution that applied to low-dose CT and chest CT images. It also provides SkyMARU:SECURITY, an AI-powered automated X-ray screening solution for enhanced aviation security; DEEP:SECURITY, an AI-powered automated X-ray screening solution for Enhanced Enterprise Security; and DEEP:FACTORY, a deep learning-based machine vision solution developed by Deepnoid for factory automation. The company was founded in 2008 and is based in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
DEEPNOID Inc reported revenue of 7.5B KRW in FY2025 versus 944M KRW in FY2021, a compound +67.7%/yr. Reported net income was −10.7B KRW in FY2025.
315640 screens 69% overvalued. Compare with Veeva Systems Inc →
Peer Group
Health Information Services · 126 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $190.12 | $95.12 | -50% |
| Pro Medicus Limited PME | A$194.84 | A$23.74 | -88% |
| BrightSpring Health Services, Inc BTSG | $68.16 | $21.31 | -69% |
| HealthEquity, Inc HQY | $97.67 | $56.63 | -42% |
| Hinge Health, Inc HNGE | $88.80 | $24.03 | -73% |
| 10x Genomics, Inc TXG | $45.75 | $17.18 | -62% |
| Waystar Holding WAY | $22.69 | $12.86 | -43% |
| Doximity, Inc DOCS | $22.21 | $17.18 | -23% |
| Privia Health Group PRVA | $28.10 | $5.30 | -81% |
| Inventurus Knowledge Solutions Limited IKS | ₹1,846 | ₹860.28 | -53% |
Compare DEEPNOID Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is DEEPNOID Inc (315640) overvalued or undervalued?
What is the fair value of 315640?
What is the quality score of 315640?
What is the revenue of DEEPNOID Inc (315640)?
What is the net profit margin of 315640?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track DEEPNOID Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.